Cryoport’s IntegriCell cryopreservation services have been selected by Verismo Therapeutics to support the company...
Servier has enrolled the first U.S. patient in a Phase Ib/II first-in-human clinical study evaluating an investigational...
Ollin Biosciences has completed an oversubscribed US$330 million Series B financing to advance global Phase III developm...
Innovent Biologics has dosed the first patient in the Chinese pivotal Phase III TriadicMM-1 trial of IBI3003 for relapse...
CeleCor Therapeutics has completed submission of its New Drug Application to the U.S. FDA for zalunfiban, its investigat...
Phanes Therapeutics has completed enrolment in its Phase II study of spevatamig in combination with standard-of-care che...
The search for safer and more effective pain therapies remains one of medicine's most pressing challenges. Despite advan...
Cancer immunotherapy is entering a new phase—one that extends beyond targeting individual tumour cells and towards...
As biotechnology enters an increasingly data-driven era, organisations are rethinking how discovery, clinical developmen...
Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced ...
Insilico Medicine has completed first-in-human dosing in the Phase I clinical study of ISM8969, an AI-driven small-molec...
The Tang Prize Foundation has awarded the 2026 Tang Prize in Biopharmaceutical Science to three pioneers of cellular imm...
Niowave and Ratio Therapeutics have signed a supply agreement for Actinium-225, strengthening Ratio’s access to a ...
FedEx has highlighted the need for more integrated, intelligent and sustainable pharmaceutical logistics networks in Asi...
Hillhurst Bio has dosed the first subject in its Phase 2a clinical trial evaluating HBI-002 for the treatment of Parkins...
Neurocrine Biosciences has presented the first retrospective case series of CRENESSITY in patients with classic congenit...
Minghui Pharmaceutical has presented complete Phase I/II clinical data for MHB018A, a subcutaneous anti-IGF-1R antibody ...
Lundbeck has presented preliminary Phase II Part A data for asedebart, an investigational anti-adrenocorticotropic hormo...
CARsgen Therapeutics has presented new clinical data for two allogeneic CAR-T cell therapy candidates, CT0596 and CT1190...
Rznomics has presented interim Phase 1/2a clinical data for RZ-001, its RNA editing-based anticancer gene therapy for re...
Genentech has received U.S. FDA acceptance and Priority Review for its New Drug Application for giredestrant as an adjuv...
Nuvalent has received U.S. FDA acceptance and Priority Review for its New Drug Application for neladalkib in tyrosine ki...
Sanofi has received European Commission approval for subcutaneous Sarclisa, or isatuximab, in combination with standard-...
MEDIPOST has secured FDA agreement to conduct a single pivotal Phase III study for CARTISTEM in the US, marking an impor...
Pfizer has received US FDA approval for an expanded indication of Hympavzi for hemophilia A or B, broadening its use to ...
